The stock of Sarepta Therapeutics Inc. (NASDAQ:SRPT) last traded at $127.26, up 0.70% from the previous session.
Data from the available sources indicates that Sarepta Therapeutics Inc. (NASDAQ:SRPT) is covered by 21 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $190.00 and a low of $101.00, we find $150.00. Given the previous closing price of $126.37, this indicates a potential upside of 18.7 percent. SRPT stock price is now 9.41% away from the 50-day moving average and 33.39% away from the 200-day moving average. The market capitalization of the company currently stands at $11.36B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 4 analysts have assigned it a hold rating, and 15 have given it a buy rating. Brokers who have rated the stock have averaged $146.42 as their price target over the next twelve months.
With the price target enhanced from $125 to $160, BTIG Research maintained Buy rating for Sarepta Therapeutics Inc. (NASDAQ: SRPT). On December 16, 2022, UBS Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock increasing its target price from $100 to quote $158, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’.
In other news, Mayo Stephen, Director sold 858 shares of the company’s stock on Nov 17. The stock was sold for $94,311 at an average price of $109.92. Upon completion of the transaction, the Director now directly owns 6,387 shares in the company, valued at $0.81 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 14, Director Chambers Michael Andrew bought 57,100 shares of the business’s stock. A total of $5,963,124 was incurred on buying the stock at an average price of $104.43. This leaves the insider owning 108,178 shares of the company worth $13.77 million. Insiders disposed of 11,626 shares of company stock worth roughly $1.48 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SRPT stock. A new stake in Sarepta Therapeutics Inc. shares was purchased by AVIDITY PARTNERS MANAGEMENT LP during the first quarter worth $120,668,000. WESTFIELD CAPITAL MANAGEMENT CO LP invested $75,696,000 in shares of SRPT during the first quarter. In the first quarter, PERCEPTIVE ADVISORS LLC acquired a new stake in Sarepta Therapeutics Inc. valued at approximately $32,197,000. CORMORANT ASSET MANAGEMENT, LP acquired a new stake in SRPT for approximately $25,452,000. IRON TRIANGLE PARTNERS LP purchased a new stake in SRPT valued at around $19,089,000 in the second quarter. In total, there are 483 active investors with 89.10% ownership of the company’s stock.
With an opening price of $127.28 on Thursday morning, Sarepta Therapeutics Inc. (NASDAQ: SRPT) set off the trading day. During the past 12 months, Sarepta Therapeutics Inc. has had a low of $61.28 and a high of $134.08. As of last week, the company has a debt-to-equity ratio of 3.58, a current ratio of 4.40, and a quick ratio of 4.00. The fifty day moving average price for SRPT is $116.32 and a two-hundred day moving average price translates $95.41 for the stock.
The latest earnings results from Sarepta Therapeutics Inc. (NASDAQ: SRPT) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$2.65, missing analysts’ expectations of -$1.18 by -1.47. This compares to -$0.60 EPS in the same period last year. The net profit margin was -81.80% and return on equity was -97.40% for SRPT. The company reported revenue of $230.27 million for the quarter, compared to $189.41 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 21.57 percent. For the current quarter, analysts expect SRPT to generate $234.52M in revenue.
Sarepta Therapeutics Inc.(SRPT) Company Profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
